Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The long-term activity ratios demonstrate a consistent downward trend from March 2022 through March 2026, indicating a decline in the efficiency of asset and equity utilization relative to revenue generation. The most significant reductions occurred during the 2022 fiscal year, followed by a period of relative stabilization with a gradual further decline through 2025.
- Net Fixed Asset Turnover
- A substantial decrease is observed, with the ratio falling from a peak of 4.64 in March 2022 to a low of 2.80 in December 2025. The sharpest decline took place between March 2022 and December 2022, where the ratio dropped from 4.64 to 3.23. Since 2023, the ratio has remained relatively stable but continued a slow downward trajectory, ending at 2.83 in March 2026. This trend suggests that investments in fixed assets have grown at a faster rate than the corresponding increase in revenue.
- Total Asset Turnover
- Overall asset utilization efficiency diminished over the analyzed period. The ratio began at 0.63 in March 2022 and declined to 0.42 by December 2022. For the subsequent three years, the ratio fluctuated within a narrow range between 0.35 and 0.41, reaching its lowest point of 0.35 in late 2025 before recovering slightly to 0.37 in March 2026. This indicates a systemic reduction in the revenue generated per unit of total assets.
- Equity Turnover
- The equity turnover ratio followed a pattern similar to the asset turnover ratios, declining from 0.83 in March 2022 to 0.47 in March 2026. A significant contraction occurred in 2022, moving from 0.83 to 0.54. From 2023 onward, the ratio exhibited a slow, steady decline, bottoming at 0.46 in late 2025. This progression suggests that the growth in shareholders' equity has outpaced the growth in sales, leading to a lower return on equity from an operational efficiency standpoint.
In summary, the synchronized decline across all three activity ratios points toward an expansion of the balance sheet that has not been matched by proportional growth in top-line revenue. The stabilization observed from 2023 through 2026 suggests the company has entered a phase of lower but more consistent asset productivity following the initial volatility seen in 2022.
Net Fixed Asset Turnover
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Property, plant, and equipment, net | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Net fixed asset turnover
= (RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025)
÷ Property, plant, and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The net fixed asset turnover ratio exhibits a sustained downward trajectory over the analyzed period, declining from 4.64 in March 2022 to 2.83 by March 2026. This trend indicates that the growth in the company's investment in fixed assets has outpaced the growth in revenue generation, resulting in a decrease in the efficiency with which net property, plant, and equipment are utilized to produce sales.
- Revenue Performance
- Revenues show an overall upward trend with periodic fluctuations. Starting at approximately 2.97 billion USD in March 2022, revenues reached a peak of approximately 3.88 billion USD in December 2025 before moderating to 3.61 billion USD in March 2026. Despite these quarterly variations, the long-term revenue trajectory is positive.
- Fixed Asset Investment
- Net property, plant, and equipment have increased consistently and linearly throughout the period. The value rose from 3.56 billion USD in March 2022 to 5.27 billion USD in March 2026. This steady accumulation of assets suggests a continuous capital expenditure program aimed at expanding production capacity or infrastructure.
- Asset Turnover Efficiency
- The decline in the net fixed asset turnover ratio is most pronounced during the first year of the analysis, dropping from 4.64 to 3.23 by December 2022. Following this initial sharp decline, the ratio remained relatively stable between 3.00 and 3.27 for several quarters before entering another gradual decline starting in June 2024, eventually reaching 2.83. This suggests that while the company is scaling its physical infrastructure, the corresponding increase in revenue has not occurred at a proportional rate, leading to lower asset productivity.
Total Asset Turnover
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Total asset turnover
= (RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The total asset turnover ratio exhibits a sustained downward trend over the analyzed period from March 31, 2022, to March 31, 2026. This decline indicates a reduction in the efficiency with which the company utilizes its total asset base to generate sales revenue.
- Revenue Trajectory
- Revenues showed an overall growth pattern, increasing from US$ 2,965,100 thousand in March 2022 to a peak of US$ 3,884,300 thousand in December 2025. While quarterly volatility is present—specifically a dip in March 2026 to US$ 3,605,400 thousand—the general trend reflects an expansion in top-line performance.
- Asset Base Expansion
- Total assets grew consistently and aggressively throughout the period. The asset base expanded from US$ 26,348,700 thousand in March 2022 to US$ 40,868,800 thousand by March 2026. This steady increase suggests significant investment in long-term resources or a substantial accumulation of assets.
- Total Asset Turnover Analysis
- The ratio experienced its most significant decline during 2022, falling from 0.63 in March to 0.42 by December. From 2023 through March 2026, the ratio entered a period of relative stabilization, fluctuating narrowly between 0.35 and 0.41. The persistent decline in the turnover ratio, despite the increase in absolute revenues, confirms that the growth in the asset base significantly outpaced the growth in revenue generation.
In summary, the data reveals a divergence between asset accumulation and revenue growth. The diminishing asset turnover ratio suggests that each dollar of assets is producing progressively less revenue over time, reflecting a decrease in operational asset efficiency.
Equity Turnover
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Equity turnover
= (RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025)
÷ Stockholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The equity turnover ratio exhibits a persistent downward trajectory over the analyzed period, declining from 0.83 in March 2022 to 0.47 by March 2026. This trend indicates a reduction in the efficiency with which stockholders' equity is utilized to generate revenue.
- Revenue Performance
- Revenues demonstrate an overall upward trend, increasing from US$ 2,965.1 million in March 2022 to US$ 3,605.4 million in March 2026. While the growth is positive, the trajectory is characterized by cyclical quarterly fluctuations, with peak performance observed in December 2025 at US$ 3,884.3 million.
- Stockholders' Equity Expansion
- Stockholders' equity shows a consistent and significant increase, rising from US$ 19,914.7 million in March 2022 to US$ 31,423.6 million by March 2026. Unlike revenues, the growth in equity is steady and linear, suggesting a continuous accumulation of capital or retained earnings over the observed timeframe.
- Equity Turnover Dynamics
- The contraction of the equity turnover ratio is driven by the fact that the growth rate of the capital base has outpaced the growth rate of revenues. A sharp decline occurred during 2022, where the ratio dropped from 0.83 to 0.54. From March 2023 through March 2026, the ratio entered a phase of gradual attrition, stabilizing between 0.53 and 0.46. This pattern suggests that each dollar of equity is generating progressively less revenue, reflecting a decrease in asset productivity relative to the company's equity growth.